Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis plan

Naohiro Yonemoto, Shiro Tanaka, Toshi A Furukawa, Tadashi Kato, Akio Mantani, Yusuke Ogawa, Aran Tajika, Nozomi Takeshima, Yu Hayasaka, Kiyomi Shinohara, Kazuhira Miki, Masatoshi Inagaki, Shinji Shimodera, Tatsuo Akechi, Mitsuhiko Yamada, Norio Watanabe, Gordon H Guyatt, SUN(^_^)D Investigators, Naohiro Yonemoto, Shiro Tanaka, Toshi A Furukawa, Tadashi Kato, Akio Mantani, Yusuke Ogawa, Aran Tajika, Nozomi Takeshima, Yu Hayasaka, Kiyomi Shinohara, Kazuhira Miki, Masatoshi Inagaki, Shinji Shimodera, Tatsuo Akechi, Mitsuhiko Yamada, Norio Watanabe, Gordon H Guyatt, SUN(^_^)D Investigators

Abstract

Background: SUN(^_^)D, the Strategic Use of New generation antidepressants for Depression, is an assessor-blinded, parallel-group, multicenter pragmatic mega-trial to examine the optimum treatment strategy for the first- and second-line treatments for unipolar major depressive episodes. The trial has three steps and two randomizations. Step I randomization compares the minimum and the maximum dosing strategy for the first-line antidepressant. Step II randomization compares the continuation, augmentation or switching strategy for the second-line antidepressant treatment. Step III is a naturalistic continuation phase. The original protocol was published in 2011, and we hereby report its updated protocol including the statistical analysis plan.

Results: We implemented two important changes to the original protocol. One is about the required sample size, reflecting the smaller number of dropouts than had been expected. Another is in the organization of the primary and secondary outcomes in order to make the report of the main trial results as pertinent and interpretable as possible for clinical practices. Due to the complexity of the trial, we plan to report the main results in two separate reports, and this updated protocol and the statistical analysis plan have laid out respective primary and secondary outcomes and their analyses. We will convene the blind interpretation committee before the randomization code is broken.

Conclusion: This paper presents the updated protocol and the detailed statistical analysis plan for the SUN(^_^)D trial in order to avoid reporting bias and data-driven results.

Trial registration: ClinicalTrials.gov: NCT01109693 (registered on 21 April 2010).

Figures

Fig. 1
Fig. 1
Flow diagram of the trial

References

    1. Furukawa TA, Akechi T, Shimodera S, Yamada M, Miki K, Watanabe N, et al. Strategic use of new generation antidepressants for depression: SUN(^_^)D study protocol. Trials. 2011;12:116. doi: 10.1186/1745-6215-12-116.
    1. American Psychiatric Association Practice guideline for the treatment of patients with major depressive disorder (third edition). American Psychiatric Association. Am J Psychiatry. 2010;167(Suppl):1–152.
    1. NICE . Depression: the treatment and management of depression in adults (partial update of NICE clinical guideline 23) London: National Institute for Clinical Excellence; 2009.
    1. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA. 1999;282:1737–44. doi: 10.1001/jama.282.18.1737.
    1. Muramatsu K, Miyaoka H, Kamijima K, Muramatsu Y, Yoshida M, Otsubo T, et al. The patient health questionnaire, Japanese version: validity according to the mini-international neuropsychiatric interview-plus. Psychol Rep. 2007;101(3 Pt 1):952–60.
    1. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606–13. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Pinto-Meza A, Serrano-Blanco A, Penarrubia MT, Blanco E, Haro JM. Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone? J Gen Intern Med. 2005;20:738–42. doi: 10.1111/j.1525-1497.2005.0144.x.
    1. Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231–42. doi: 10.1056/NEJMoa052963.
    1. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–52. doi: 10.1056/NEJMoa052964.
    1. Beck AT, Steer RA, Brown GK. BDI-II: Beck Depression Inventory, second edition, manual. San Antonia: The Psychological Corporation; 1996.
    1. Kojima M, Furukawa T, Takahashi H, Kawai M, Nagaya T, Tokudome S. Cross-cultural validation of the Beck Depression Inventory-II in Japan. Psychiatry Res. 2002;110:291–9. doi: 10.1016/S0165-1781(02)00106-3.
    1. Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry. 2007;164:1035–43. doi: 10.1176/appi.ajp.164.7.1035.
    1. Bruce ML, Ten Have TR, Reynolds CF, 3rd, Katz II, Schulberg HC, Mulsant BH, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA. 2004;291:1081–91. doi: 10.1001/jama.291.9.1081.
    1. Wells KB, Sherbourne C, Schoenbaum M, Duan N, Meredith L, Unutzer J, et al. Impact of disseminating quality improvement programs for depression in managed primary care: a randomized controlled trial. JAMA. 2000;283:212–20. doi: 10.1001/jama.283.2.212.
    1. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988;75:800–2. doi: 10.1093/biomet/75.4.800.
    1. Jarvinen TL, Sihvonen R, Bhandari M, Sprague S, Malmivaara A, Paavola M, et al. Blinded interpretation of study results can feasibly and effectively diminish interpretation bias. J Clin Epidemiol. 2014;67:769–72. doi: 10.1016/j.jclinepi.2013.11.011.
    1. Sihvonen R, Paavola M, Malmivaara A, Itala A, Joukainen A, Nurmi H, et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013;369:2515–24. doi: 10.1056/NEJMoa1305189.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera